TY - JOUR
T1 - Mucosal leishmaniasis in travelers with leishmania braziliensis complex returning to israel
AU - Solomon, Michal
AU - Sahar, Nadav
AU - Pavlotzky, Felix
AU - Barzilai, Aviv
AU - Jaffe, Charles L.
AU - Nasereddin, Abedelmajeed
AU - Schwartz, Eli
N1 - Publisher Copyright:
© 2019, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2019/4
Y1 - 2019/4
N2 - Mucosal leishmaniasis (ML) is a complication of New World cutaneous leishmaniasis (CL) caused mainly by Leishmania (Viannia) braziliensis. This retrospective study investigated all cases of ML caused by L. (V.) braziliensis in a tertiary medical center in Israel, evaluating the risk factors, clinical presentations, diagnosis, treatment, and outcome of mucosal involvement in ML caused by L. (V.) braziliensis in travelers returning to Israel. During 1993–2015, a total of 145 New World CL cases were seen in travelers returning from Bolivia; among them, 17 (11.7%) developed ML. Nasopharyngeal symptoms developed 0–3 years (median 8 months) after exposure. The only significant risk factor for developing ML was the absence of previous systemic treatment. Among untreated patients, 41% developed ML, compared with only 3% of treated patients (p = 0.005). Systemic treatment for CL seems to be a protective factor against developing ML.
AB - Mucosal leishmaniasis (ML) is a complication of New World cutaneous leishmaniasis (CL) caused mainly by Leishmania (Viannia) braziliensis. This retrospective study investigated all cases of ML caused by L. (V.) braziliensis in a tertiary medical center in Israel, evaluating the risk factors, clinical presentations, diagnosis, treatment, and outcome of mucosal involvement in ML caused by L. (V.) braziliensis in travelers returning to Israel. During 1993–2015, a total of 145 New World CL cases were seen in travelers returning from Bolivia; among them, 17 (11.7%) developed ML. Nasopharyngeal symptoms developed 0–3 years (median 8 months) after exposure. The only significant risk factor for developing ML was the absence of previous systemic treatment. Among untreated patients, 41% developed ML, compared with only 3% of treated patients (p = 0.005). Systemic treatment for CL seems to be a protective factor against developing ML.
UR - http://www.scopus.com/inward/record.url?scp=85063300951&partnerID=8YFLogxK
U2 - 10.3201/eid2504.180239
DO - 10.3201/eid2504.180239
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30882319
AN - SCOPUS:85063300951
SN - 1080-6040
VL - 25
SP - 642
EP - 648
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 4
ER -
